当前位置:
X-MOL 学术
›
Nat. Rev. Neurol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Preparing for disease-modifying dementia therapies in the UK
Nature Reviews Neurology ( IF 28.2 ) Pub Date : 2024-09-17 , DOI: 10.1038/s41582-024-01022-1 Claudia Cooper 1 , Charles R Marshall 1 , Jonathan M Schott 2 , Sube Banerjee 3
Nature Reviews Neurology ( IF 28.2 ) Pub Date : 2024-09-17 , DOI: 10.1038/s41582-024-01022-1 Claudia Cooper 1 , Charles R Marshall 1 , Jonathan M Schott 2 , Sube Banerjee 3
Affiliation
Although lecanemab has been licensed for use in the UK, the systems to deliver this or similar disease-modifying therapies do not exist. These systems need to be developed urgently, but not at the expense of post-diagnostic care.
中文翻译:
在英国为改善病情的痴呆治疗做准备
尽管 lecanemab 已获得在英国的许可使用,但不存在提供这种或类似疾病缓解疗法的系统。这些系统需要紧急开发,但不能以牺牲诊断后护理为代价。
更新日期:2024-09-17
中文翻译:
在英国为改善病情的痴呆治疗做准备
尽管 lecanemab 已获得在英国的许可使用,但不存在提供这种或类似疾病缓解疗法的系统。这些系统需要紧急开发,但不能以牺牲诊断后护理为代价。